Evidence-Based Medicine Guidelines
Regular vs. as-needed inhaled short acting beta2-agonist use in asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Regular Vs. As-needed Inhaled Short Acting Beta2-agonist Use in Asthma." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452510/all/Regular_vs__as_needed_inhaled_short_acting_beta2_agonist_use_in_asthma.
Regular vs. as-needed inhaled short acting beta2-agonist use in asthma. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/452510/all/Regular_vs__as_needed_inhaled_short_acting_beta2_agonist_use_in_asthma. Accessed July 17, 2025.
Regular vs. as-needed inhaled short acting beta2-agonist use in asthma. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/452510/all/Regular_vs__as_needed_inhaled_short_acting_beta2_agonist_use_in_asthma
Regular Vs. As-needed Inhaled Short Acting Beta2-agonist Use in Asthma [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 July 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452510/all/Regular_vs__as_needed_inhaled_short_acting_beta2_agonist_use_in_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Regular vs. as-needed inhaled short acting beta2-agonist use in asthma
ID - 452510
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452510/all/Regular_vs__as_needed_inhaled_short_acting_beta2_agonist_use_in_asthma
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
